Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study (mentor™6)
This study is conducted globally. The aim of this observational study is to investigate the incidence of specific adverse drug reactions associated with the use of recombinant factor XIII (NovoThirteen®) in patients with congenital FXIII A-subunit deficiency (congenital FXIII deficiency), comprising FXIII antibodies, allergic reactions, embolic and thrombotic events and lack of therapeutic effect.
The study will aim at observing all patients exposed to NovoThirteen® in the EU, and additional patients from selected non-EU countries. Recombinant FXIII (rFXIII) is registered in EU and Switzerland as NovoThirteen® and in Canada as Tretten®.
研究概览
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
Newfoundland and Labrador
-
St. John's、Newfoundland and Labrador、加拿大、A1B 3V6
- Novo Nordisk Investigational Site
-
-
Ontario
-
Toronto、Ontario、加拿大、M5G 1X8
- Novo Nordisk Investigational Site
-
-
-
-
-
Debrecen、匈牙利、4012
- Novo Nordisk Investigational Site
-
-
-
-
-
Chieti、意大利、66100
- Novo Nordisk Investigational Site
-
Genova、意大利、16147
- Novo Nordisk Investigational Site
-
-
-
-
California
-
Orange、California、美国、92868
- Novo Nordisk Investigational Site
-
-
Florida
-
Tampa、Florida、美国、33607
- Novo Nordisk Investigational Site
-
-
Georgia
-
Atlanta、Georgia、美国、30322
- Novo Nordisk Investigational Site
-
-
Michigan
-
Detroit、Michigan、美国、48201
- Novo Nordisk Investigational Site
-
-
Minnesota
-
Minneapolis、Minnesota、美国、55404
- Novo Nordisk Investigational Site
-
-
Ohio
-
Cleveland、Ohio、美国、44106
- Novo Nordisk Investigational Site
-
Columbus、Ohio、美国、43205
- Novo Nordisk Investigational Site
-
-
-
-
-
Aberdeen、英国、AB25 2ZN
- Novo Nordisk Investigational Site
-
-
-
-
-
Barcelona、西班牙、08035
- Novo Nordisk Investigational Site
-
Madrid、西班牙、28046
- Novo Nordisk Investigational Site
-
Málaga、西班牙、29011
- Novo Nordisk Investigational Site
-
Tortosa、西班牙、43500
- Novo Nordisk Investigational Site
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- Informed consent obtained before any study-related activities. (Study-related activities are any procedure related to recording of data according to the protocol)
- Able and willing to provide signed informed consent (or patient's legally acceptable representative (LAR) consent, if applicable), as required by local ethics committee, governmental or regulatory authorities
- Congenital FXIII A-subunit deficiency
- Actual or planned exposure to rFXIII
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
---|---|
rFXIII
|
No treatment given.
All patients enrolled in this observational study will receive their medication through usual commercial channels.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
Adverse drug reactions in patients with congenital FXIII A-subunit deficiency treated with rFXIII,comprising FXIII antibodies, allergic reactions, embolic and thrombotic events and lack of effect collected
大体时间:During study period up to 6 years
|
During study period up to 6 years
|
次要结果测量
结果测量 |
大体时间 |
---|---|
All serious adverse events collected
大体时间:During study period up to 6 years
|
During study period up to 6 years
|
All medical events of special interest collected
大体时间:During study period up to 6 years
|
During study period up to 6 years
|
All medication errors and near medication errors collected
大体时间:During study period up to 6 years
|
During study period up to 6 years
|
Use of rFXIII in patients with congenital FXIII A-subunit deficiency also for other uses than for prophylactic treatment collected
大体时间:During study period up to 6 years
|
During study period up to 6 years
|
Frequency of bleeding episodes collected
大体时间:During study period up to 6 years
|
During study period up to 6 years
|
合作者和调查者
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
先天性出血性疾病的临床试验
-
Hospital Universitari Vall d'Hebron Research InstituteInstituto de Salud Carlos III完全的
-
Dren BioNovotech招聘中侵袭性 NK 细胞白血病 | 肝脾T细胞淋巴瘤 | 肠病相关的T细胞淋巴瘤 | 皮下脂膜炎样 T 细胞淋巴瘤 | 单形性趋上皮性肠 T 细胞淋巴瘤 | LGLL - 大颗粒淋巴细胞白血病 | 原发性皮肤 T 细胞淋巴瘤 - 类别 | 原发性皮肤 CD8 阳性侵袭性嗜表皮 T 细胞淋巴瘤 | 系统性 EBV1 T 细胞淋巴瘤,如果 CD8 阳性 | Hydroa Vacciniforme-Like Lymphoproliferative Disorder | 结外 NK/T 细胞淋巴瘤,鼻型 | 胃肠道惰性慢性淋巴增生性疾病 (CLPD)(CD8+ 或 NK 衍生) | 上面未列出的其他 CD8+/NK 细胞驱动的淋巴瘤美国, 澳大利亚, 法国, 西班牙
-
Memorial Sloan Kettering Cancer Center招聘中蕈样肉芽肿 | 塞扎里综合症 | 血管免疫母细胞性T细胞淋巴瘤 | 肝脾T细胞淋巴瘤 | 间变性大细胞淋巴瘤,ALK 阳性 | 结外 NK/T 细胞淋巴瘤,鼻型 | T细胞淋巴瘤 | 未特指的外周 T 细胞淋巴瘤 | 原发性皮肤间变性大细胞淋巴瘤 | 皮下脂膜炎样 T 细胞淋巴瘤 | 肠病相关的T细胞淋巴瘤 | 间变性大细胞淋巴瘤,ALK 阴性 | 单形性趋上皮性肠 T 细胞淋巴瘤 | T 细胞幼淋巴细胞白血病 | T 细胞大颗粒淋巴细胞白血病 | 原发性皮肤 CD8 阳性侵袭性嗜表皮 T 细胞淋巴瘤 | Hydroa Vacciniforme-Like Lymphoproliferative Disorder | NK细胞淋巴瘤 | 侵袭性 NK 细胞白血病 | 成人 T 细胞白血病/淋巴瘤 及其他条件美国